Sun.Sep 18, 2022

article thumbnail

Acelyrin’s $300M haul for novel biologic leads a slate of biotech financings

MedCity News

The biggest biotech financing of the past week belongs to a startup developing an immunology drug that could rival blockbuster products sold by big pharmaceutical companies. Cell therapy, cancer, and rare disease also figured into this week’s startup cash hauls.